Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

the similarity between FYB206 and Keytruda® was confirmed across multiple parameters such as structure, purity, and potency. This comprehensive data package lays a strong foundation for the ...

In just the past two years, the S&P 500 has amassed some incredible gains, rising by around 60% during that stretch. It's an incredible performance when you consider its long-run average is a return ...

Keytruda's market leadership continues to grow ... And as we said, we would expect to ship about the same amount in the fourth quarter. So you should expect that the fourth quarter itself would ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... of a superior data package, including stability data ...

Merck's Q2 beat was driven by strong Keytruda sales and growth in oncology ... expected sales of the Gardasil vaccine, impacted by shipment delays in China. Merck's lowered adjusted profit ...

Keytruda has been a top-selling drug for years ... Carvana will need to run a tight ship to ensure it is able to stay out of the red. Last year, it incurred an operating loss of $72 million.

AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”) today announced that the Company has filed its definitive proxy ...